Author: Solu Therapeutics

Solu Therapeutics to Present Initial Phase 1 Results of STX-0712 and New Preclinical Data on STX-0640 in Two Oral Presentations at the 2026 ASH Annual Meeting

November 4, 2026
Solu Therapeutics Initiates Dosing in Acute Myeloid Leukemia Cohort of the Ongoing Phase 1 Study of STX-0712

October 8, 2026

Solu Therapeutics to Present Initial Phase 1 Results of STX-0712 and New Preclinical Data on STX-0640 in Two Oral Presentations at the 2026 ASH Annual Meeting